Vegetarian Protein A Production via Synthetic Media and Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing Protein A for human therapeutics involve contamination risks due to animal-derived products in the growth media and purification processes, making it difficult to eliminate animal product contamination completely.
Innovation Solution
A method involving fermentation of Staphylococcus aureus secretor strains in vegetarian media, followed by purification using synthetic resins and chromatography techniques such as anion exchange and hydroxyapatite chromatography, to produce Protein A free from animal-derived contaminants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods using animal-derived products in growth media and purification processes are used, then Protein A production is efficient and established, but contamination with animal products occurs making it unsafe for human therapeutics
Solution Approach 1:
The patent removes animal-derived components from the entire production process. This includes using synthetic or plant-based media components instead of animal sera and extracts, and employing synthetic resins instead of animal-derived Sepharose for chromatography. By extracting and eliminating the harmful animal-derived elements, the patent achieves safe Protein A production for human therapeutics without contamination risks.
Solution Approach 2:
The patent introduces synthetic or plant-based intermediary substances to replace animal-derived components. These include synthetic amino acids, plant-based extracts, and synthetic chromatography resins that serve as mediators between the production needs and the safety requirements, enabling Protein A production without animal product contamination.
2Productivity
If animal-derived products like bovine hydrolysates are used in bacterial growth media, then bacterial growth and Protein A production are enhanced, but risk of prion transmission to human patients increases
Solution Approach 1:
The patent converts the potential harm of using rich animal-derived media into benefit by deliberately selecting synthetic or plant-based media components that can provide equivalent or superior nutritional support for bacterial growth. This approach eliminates prion transmission risk while maintaining or enhancing Protein A production yield through optimized synthetic media formulations.
Solution Approach 2:
The patent changes the fundamental parameter of media composition from animal-derived to synthetic or plant-based components. This parameter change fundamentally alters the safety profile by eliminating prion transmission risk while maintaining productivity through carefully optimized concentrations of synthetic amino acids, carbon sources, and growth factors.
3Manufacturing precision
If IgG Sepharose chromatography columns are used for Protein A purification, then purification efficiency is high, but contamination with animal products occurs that cannot be easily removed
Solution Approach 1:
The patent extracts and removes animal-derived Sepharose from the purification process, replacing it with synthetic chromatography resins. This extraction of the harmful animal-derived component eliminates the source of contamination while maintaining the chromatographic separation capability needed for high-purity Protein A purification.
Solution Approach 2:
The patent creates synthetic copies of the functional properties of animal-derived Sepharose. The synthetic resins replicate the chromatographic separation capabilities, binding specificity, and purification efficiency of traditional Sepharose columns without containing any animal-derived materials, thus achieving the same manufacturing precision without contamination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures the production of vegetarian Protein A that is free from animal product contamination, enabling its safe use in human therapeutics and pharmaceutical applications, including antibody purification and treatment of autoimmune diseases and cancer.
Implementation Method 1
fermenting an S. aureus secretor strain in a specific media
Implementation Method 2
purifying the Protein A by applying it to a synthetic resin that lacks animal peptides and filtering the elutant from the resin
Implementation Method 3
The vegetarian Protein A eluted from the chromatography resin is further purified by hydroxyapatite chromatography to remove non-proteineous contaminants
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to methods of producing Protein A without contamination of the Protein A by animal products. The invention also relates to a vegetarian fermentation media in which Staphylococcus aureus is grown to produce a vegetarian Protein A. The invention further relates to a vegetarian Protein A and the use of a vegetarian Protein A in therapeutic and prophylactic methods.